Peptide neuroprotection through specific interaction with brain tubulin

被引:103
作者
Divinski, Inna [1 ]
Holtser-Cochav, Miri [1 ]
Vulih-Schultzman, Inna [1 ]
Steingart, Ruth A. [1 ]
Gozes, Illana [1 ]
机构
[1] Tel Aviv Univ, Sackler Fac Med, Dept Human Mol Genet & Biochem, IL-69978 Tel Aviv, Israel
关键词
activity-dependent neuroprotective protein; beta III-tubulin; microtubules; NAP; taxol;
D O I
10.1111/j.1471-4159.2006.03936.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This study aimed to identify the neuronal target for the potent neuroprotective peptide NAP. When added to pheochromocytoma cells (neuronal model), NAP was found in the intracellular milieu and was co-localized with microtubules. NAP induced neurite outgrowth and protected primary neurons against microtubule-associated ZnCl2 toxicity. Rapid microtubule reorganization into distinct microtubules ensued after NAP addition to both pheochromocytoma cells and primary cerebral cortical neurons, but not to fibrobalsts. While binding neuronal tubulin and protecting pheochromocytoma cells against oxidative stress, NAP did not bind tubulin extracted from fibroblasts, nor did it protect those cells against oxidative stress. Affinity chromatography identified the brain-specific beta III-tubulin as a major NAP binding protein. Paclitaxel (a microtubule aggregating agent that interacts with beta-tubulin) reduced NAP tubulin binding. Thus, the underlying mechanism for the neuroprotection offered by NAP is targeting neuronal microtubules that are essential for neuronal survival and function.
引用
收藏
页码:973 / 984
页数:12
相关论文
共 57 条
[1]   Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze [J].
Alcalay, RN ;
Giladi, E ;
Pick, CG ;
Gozes, I .
NEUROSCIENCE LETTERS, 2004, 361 (1-3) :128-131
[2]  
BANERJEE A, 1990, J BIOL CHEM, V265, P1794
[3]   Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide [J].
Bassan, M ;
Zamostiano, R ;
Davidson, A ;
Pinhasov, A ;
Giladi, E ;
Perl, O ;
Bassan, H ;
Blat, C ;
Gibney, G ;
Glazner, G ;
Brenneman, DE ;
Gozes, I .
JOURNAL OF NEUROCHEMISTRY, 1999, 72 (03) :1283-1293
[4]   MAPREG - Toward a novel approach of neuroprotection and treatment of Alzheimer's disease [J].
Baulieu, EE ;
Robel, P ;
Fellous, A ;
Duchossoy, Y ;
Fontaine-Lenoir, V ;
David, S .
JOURNAL OF MOLECULAR NEUROSCIENCE, 2004, 24 (01) :63-65
[5]  
Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57
[6]   The Neuronal Cytoskeleton as a Potential Therapeutical Target in Neurodegenerative Diseases and Schizophrenia [J].
Benitez-King, G. ;
Ramirez-Rodriguez, G. ;
Ortiz, L. ;
Meza, I .
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2004, 3 (06) :515-533
[7]   THE SURVIVAL OF DENTATE GYRUS NEURONS IN DISSOCIATED CULTURE [J].
BOSS, BD ;
GOZES, I ;
COWAN, WM .
DEVELOPMENTAL BRAIN RESEARCH, 1987, 36 (02) :199-218
[8]   A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication [J].
Divinski, I ;
Mittelman, L ;
Gozes, I .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (27) :28531-28538
[9]  
Don S, 2004, MOL CANCER THER, V3, P1137
[10]   The seco-taxane IDN5390 is able to target class III β-tubulin and to overcome paclitaxel resistance [J].
Ferlini, C ;
Raspaglio, G ;
Mozzetti, S ;
Cicchillitti, L ;
Filippetti, F ;
Gallo, D ;
Fattorusso, C ;
Campriani, G ;
Scambia, G .
CANCER RESEARCH, 2005, 65 (06) :2397-2405